CVs of selectedScientific Collaborators
D A N I C A G R U J I C P H . D .
| CELL (617) 599-3301 |
HOM E (617) 427-7085
210 PARKER HILL AVENUE | BOSTON, MA 02120
P R O F I L E
A Biopharmaceutical Scientist in a Senior Leadership position, with over 10 years of direct
research management and provision of leadership to multiple projects focused on
developing oral protein therapeutics for chronic gastrointestinal, metabolic and rare genetic
disorders. She has an excellent understanding of all phases of pharmaceutical research and
development, from methods and concepts of pharmacology, molecular and cell biology,
protein chemistry and assay development. She provides leadership and critical process
evaluation from initial phases of pre-clinical development, patent portfolio built up, IND
filing, and subsequent process development leading from early research to Phase I clinical
trials. She also supported late phase development and filing documents for NDA
submission. She has led pre-clinical programs at two companies that have been
transitioned successfully either to the public sector or acquired by other Pharmaceutical
Developed and led pre-clinical programs for testing 5 oral drug candidatesfor gastrointestinal and
metabolic disorders. Designed critical pre-clinical experiments in disease models to create
supportfor NDA filingandnovel pediatricformulation
Identified and managed CRO’s for 3 independent programs within US, Europe and Asia, mostly
focused for pre-clinical proof of concept work, but including large scale manufacturing of future
drug candidates. Negotiatedtimelinesandbudgets.
Prepared and critically revised regulatory documents including reports for NDA, IND’s, IB’s and
Conducted pre-clinical research program for gene therapy for diabetes and genetic disorders with
CNSinvolvement(Lysosomal storage diseases).
Demonstrates excellent organizational, communication and writing skills as
evidenced by effective presentations at international meetings in US and Europe,
with investment partners, external consultants, in the writing of scientific papers,
technical reports, patent applications, and Federal and European regulatory
Works closely with the business development group in support of business alliance
discussions and collaborations, serving as the lead in presentations to prospective
partners and companies.
Recognized for initiative, enthusiastic attitude, excellent interpersonal, skills, and
strong desire to solve challenging problems.
Appreciated as someone who learns and transitions quickly and effectively as
priorities change within company.
E X P E R I E N C E
ALNARA PHARMACEUTICAL, Cambridge , MA 2009-
Associate Director of Pharmacology
Leads design and implementation of critical pre-clinical studies with external collaborators to
support NDA filing and testing of a novel pediatric formulation of Liprotamase [a non-porcine
microbial-derived enzyme therapy for pancreatic insufficiency and related disorders]. Leads a
research team that develops future drug candidate for hyperuricemia, gout, and kidney stones with
European collaborators and US CROs. [most recently, testing of novel pediatric formulation of
Liprotamase with European collaborators and CROs].
Performs budget planning within R&D group and negotiates budgets with CROs and external
Works cross-functionally within the company to be the lead spokesperson for science that lends
support to critical missions of Clinical and Business Development groups.
Identifies research partners and establishes external collaborations.
Integral part of the team that writes and reviews reports for NDA filing including pharmacology
and clinical studies sections.
ALTUS PHARMACEUTICALS, MA 2004-
Directs designs, plans, and performs pre-clinical proof of concept studies for treatment of
hyperoxaluria and kidney stones, hyperuricemia and gout, and hyperphenylalanemia and PKU
Provided critical support to process development group by planning in details large scale protein
production (800L) in E.coli and Pichia with CRO’s together with large scale in house protein
purification and protein formulation using Altus proprietary technology.
Integral part of the team that prepared documentation for pre-IND and IND filling for the one of
the early research programs; member of the team that had early conversation with FDA negotiating
the requirements for the Phase I clinical trials.
Member of the team that executes toxicology studies for one of the programs prior Phase I safety
Works cross-functionally within the company to support Clinical Team for easy transfer from early
phase of the research program to development stage and Phase I clinical trial, similarly supported
Business Development group in developing partnership opportunities
Identified potential research partners and established external collaborations
Performs budget planning within R&D and negotiates budgets with CROs and external partners.
Prepares documents for regulatory and patent filings, 3 patent applications submitted within 2
Prepares protocols, contracts,batch records for externalCRO’s; data reviewed and audited, first
and corresponding author on manuscripts for publication and scientific presentations
TRANSKARYOTIC THERAPIES INC., Cambridge, MA 1999 – 2004
Directed design and implementation of future drug candidates, including biologics and small
molecules Planned, organized and performed pre-clinical studies for gene therapy diabetes project;
performed in vivo study using animal xenograft models and performed pharmacokinetic analysis
Directed and managed gene therapy diabetes project to a decision milestone
Member of a team responsible for the development of the pre-clinical program for the novel drug
candidate for treatment of lysosomal storage diseases with CNS involvement, planed and set up in
vitro experiments for protein delivery to the brain using novel technologies, analyzed data using
new developed biochemical and immunology assays
Planned, organized and executed development of cell lines in mammalian cells, E.coli and Pichia
pastoris for enzyme replacement therapy for rare metabolic disorders
Designed and managed proof of the concept experiments for the protein delivery to the specific
organs implementing novel technologies (in vitro & in vivo)
Worked cross functionally in the company with Cell Development, Protein Purification and
Animal Physiology groups as evidenced by the transfer technology, training individuals and project
advancement fulfilling strict time lines
Organized and led several review presentations of R & D projects at companywide seminars,
internal scientific forums and for senior management team
Worked closely with the business development group in support of business alliance
Supervised and trained 3-6 research scientists; effectively cascaded information from senior
management team to the group
BETH ISRAEL DEACONESS MEDICAL CENTER & HARVARD MEDICALSCHOOL,
DIVISION OF ENDOCRINOLOGY AND METABOLISM, Boston, MA 1993 – 1999
Graduate and Post-Doctoral Scientist
Conducted research in the field of obesity and diabetes focus in development of mouse model
using gene knockout and transgenic approaches
Developed mouse models which led to better understanding of the role of beta-3 and alpha 2
adrenergic receptors in the development of obesity and the potential of these genes to act as cellular
targets for anti-obesity drugs in humans
Performed discovery work in the field of uncoupling proteins, related to the UCP2 and UCP3
genes, and their potential as anti-obesity drugs
Presented results at international meetings, department and hospital seminars, and video
conferences with Eli Lilly
Supervised one research associate and taught molecular biology and physiology techniques to
endocrine and post-doctoral fellows
Tested potential anti-obesity drug candidate in different mouse model for Eli Lily and Merck
ARGONNE NATIONAL LABORATORY, Argonne, IL 1991 – 1993
Participated in the development of a novel high through put method for the Human Genome
Sequencing Project called sequencing by hybridization (SBH)
UsingSBH discoverednovel genesfrominfantbraincDNA and E. coli libraries
Workedon the identificationof carriersforthe Duchenne MuscularDystrophygene
T E C H N I C A L S K I L L S
Phase 1 clinical design and data analysis, pre-IND and IND and NDA documents writing ; design,
execution , data analysis of the critical pre-clinical experiments necessary for either IND or NDA
filling; pharmacokinetics and pharmacodynamics experiment design, Phase 1 clinical design and data
analysis, development of cell-based models and assays,generation and characterization of transgenic
and knockout animals
DNA modifying techniques, gene cloning, PCR,RT-PCR,PCR- based assays,Northern-,and Western
–blotting, protein expression in mammalian, bacterial and yeast systems, E. coli and Pichia protein
manufacturing at 800L scale, affinity protein purification, ELISA, RIA,tissue culture, in vivo and in
vitro drug testing, sample analysis (biochemical, histochemical, immunologic)
E D U C A T I O N
UNIVERSITY OF BELGRADE,YU
Ph.D.,Molecular Biology and Physiology
Research completed in Beth IsraelDeaconess MedicalCenter & Harvard Medical School
M.S., Molecular Biology and Physiology
B.S., Molecular Biology 1983
I N T E R N A T I O N A L M E E T I N G S
1. Submitted abstract to DDW 2010, NewOrleans,May 1-5, with the title “ Liprotamase, a microbial
enzyme therapy, reverses impaired growth in pigs with exocrine pancreatic insufficiency (EPI)” was
selected for oral presentation in the session Pancreatic Biology and Pathobiology.
2. Invited speaker to NIDDK Symposium 2008 “Anion Transporters and Oxalate Homeostasis: From
Genes to Disease” December 8-9th
,2008, Rockville, MD with the title: “Oxalate Degrading Enzyme in
3. Invited speaker to 11th
International Symposium on Urolithhisasi 2008,Nice,France,Sep 2-5, 2008
with two papers: “Oral therapy with ALTU-242 reduces hyperuricemia and hyperuricosuria in mice
lacking urate oxidase (uox-/-) and “Hyperoxaluria regardless of Cause is Reduced and
Nephrocalcinosis Prevented With Crystalline Oxalate Degrading Enzyme in Animal Model”.
4. Submitted abstract to ASN, Renal Week 2007,San Francisco,November 2007 with the title: “Oral
therapy with crystalline oxalate degrading enzyme reduces hyperoxaluria in rodent models." was
selected for 7 min oral presentation in the Other Mundelian Syndromes session.
5. Submitted abstract to 2007 AUA Annual Meeting,Anaheim, May 2007 with the title: Oral therapy
with crystalline formulation of oxalate degrading enzyme in rodent models with hyperoxaluria” was
selected for 5 min oral presentation at Stone Disease: Research session,and was awarded as a Best
6. Invited speaker at The BONE, STONEand the KIDNEY Satellite Symposium,Post-Congress
Official Satellite Symposium of World Congress of Nephrology (WCN 07),Angra dos Reis,Rio de
Janeiro, April 2007 with the paper: “Oxalate degrading enzymes in the treatment of primary
7. Invited speaker at annual meeting of ASN, Renal Week 2006,San Diego, November 2006 at
Bone/Stone session with the paper: “Crystalline formulation of an orally administered oxalate
degrading enzyme reduces hyperoxaluria in mouse genetic model”.
P U B L I C A T I O N S
1. Grujic D, Salido EC, Shenoy BC, Langman, CB, McGrath M, Patel RJ, Rashid A, Mandapati S, JungC,and
Margolin AL: Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading
enzyme inmice withhyperoxaluria (AJN,epub Aug,2008)
2. Boucher J, Castan-Laurell I, Le Lay S, Grujic D, Sibrac D, Krief S, Lafontan M, Lowell, B B, Dugaill I,
Saulinier-Blache, J S, Valet, P: Human alpha 2A-adrenergic receptor gene expressed in transgenic
mouse adipose tissue under the control of its regulatory elements. J Mol Endocrinology 2002
3. Visentin V, Morin N, Fontana E, Prevot D, Boucher J, Castan I, Valet P, Grujic D, Carpene C: Dual action
of octopamine on glucose transportinto adipocytes:inhibition via beta2-adenoreceptor activation
and stimulationviaoxidationbyamine oxidases. JPharmacolExp Ther.2001 Oct 299 (1):96-104
4. Zhang Cy, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vida-Puig A J, Boss O, Kim Y
B, Zheng X X, Wheeler M B, Shulman G I, Chan C B, Lowell B B: Uncoupling protein-2
negatively regulates insulin secretion and is major link between obesity, beta cell dysfunction and
type 2 diabetes. Cell 2001 Jun 15; 105(6):745-55
5. Grujic D, Valet P, Wade J, Ito M, Zingaretti M.C, Soloveva V, Ross S.R, Graves R.A, Cinti S, Lafontan M,
Lowell B.B: Expression of human alpha 2-adrenergic receptors in adipose tissue of beta 3-
adrenergic receptor-deficient mice promotes diet-induced obesity. J. Biol. Chem. 2000 Nov 3; 275
6. Vidal-Puig A J, Grujic D, Zhang C.Y, Hagen T, Boss O, Ido Y, Szczepanik , A, Wade J, Mootha V, Cortright
R, Muoio D M, Lowell B B: Energy metabolism in uncoupling protein 3 gene knockout mice. J.
Biol. Chem.2000 May 26; 275 (21): 6258-66
7. Cortright, R, Zheng, D, Jones, J P, Fluckey, J D, DiCarlo, S E, Grujic, D, Lowell, B B and Dohm, G L:
Regulation of skeletal muscle UCP-2 and UCP-3 gene expression by exercise and denervation. Am.
J. Physiol. (1999) vol 276 (1 Pt):E 217-21
8. Fletcher, D S, Candelore M R, Grujic, D, Lowell, B B, Luell, S, Susulic, S V, Macintyre, D E: Beta-3
adrenergic receptor agonist cause an increase in gastrointestinal transit time in wild-type mice,
but not in mice lacking the beta-3 adrenergic receptor. J. Pharm. Experim. Therap. (1998) vol.
287, No 2, p 720-724
9. Boyer, B, Barnes, B M, Lowell, B B and Grujic, D: Differential regulation of uncoupling protein gene
homologues in multiple tissues of hibernating ground squirrels. Am. J. Physiol. (1998): 275
(RegulatoryIntegrative Comp.Physiol. (44) R1232-1238
10. Ito, M, Grujic, D, Abel, E D, Vidal-Puig, A, Susulic, V S, Lawitts, J, Harper, M-E, Himms-Hagen, J,
Strosberg, A D and Lowell, B B: Mice expressing human but not murine b3-adrenergic receptors
underthe control of humangene regulatoryelements. Diabetes (1998) Sep47(9)1464-1470
11. Solanes, G, Vidal-Puig A, Grujic D, Flier J S, Lowell B B: The human uncoupling protein-3 gene.
Genomic structure, chromosomal location and genetic basis for short and long transcripts. J Biol
Chem 1997 Oct 10; 272(41) 25433-6
12. Grujic, D, Susulic, S V, Harper, M-E, Himms-Hagen, J, Cunningham, B, Corkey, B and Lowell B: b3-
Adrenergic receptors on white and brown adipocytes mediate b3-selective agonist-induced
effects on energy expenditure, insulin secretion and food intake. J. Biol. Chem. (1997) Jul11; 272
13. Grujic, D, Vidal-Puig, A, Solanes, G, Flier, J S, and Lowell: B B, UCP3: an uncoupling protein homologue
expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem.
Biophys.Res.Commun. (1997) 235:79-82
14. Solanes, G, C-Y. Zang, S-Susulic, V, Grujic, D, Hollenberg, T, Chung, W K, Leibel, R, and Lowell, B B:
Transgenic assessment of leptin gene transcription and characterization of the ob2j mutation.
15. Milosavljevic, A, Zeremski, M, Strezoska, Z, Grujic, D, Dyanov, H, Batus, S, Salbego D, Paunesku, T,
Soares, M B, and Crkvenjakov, R: Discovering distinct genes represented in 29,579 clones from
infant brain cDNA libraries by applying sequencing by hybridization methodology. Genome
Research (1996), 6, p132-141
16. Milosavljevic, A, Savkovic, S, Crkvenjakov, R, Salbego, D, Serrato, H, Kreuzer, H, Gemmell, A, Batus, S,
Grujic, D, Carnahan, S, Paunesku, T and Tepavcevic, J: DNA sequence recognition byhybridization
to short oligomers: experimental verification of the method on the E.coli. genome. Genomics
(1996), 37 (1),77-86
17. Milosavljevic, A, Strezoska, Z., Zeremski, M., Grujic, D., Paunesku,T., Crkvenjakov, R. Clone: clustering
by hybridization. Genomics (1995), 27 (1) p 83-9
18. Grujic, D., Strezoska, Z, and Crkvenjakov, R, High: throughput PCR procedure for up to 6-kb lengths of
DNA. Biotechniques (1994), 17, 291-294
19. McClathey, A, Trofatter, J, Mckenna-Yasek, D, Raskind, W, Bird, T, Vance, M, Gilchrist, J,
Hausmanowa-Petrusewicz, I, Arahata, K, Radosavljevic (Grujic), D, Haines, J, Gusella, J F and
Brown, R H, Dinucleotide: repeat polymorphisms at the SCN4A locus suggest allelic heterogenity
of both hyperleucemic periodic paralysis and paramiotonicongenita. American Journal of Human
Genetics, (1992), 50, 896-901
20. Strezoska, Z, Paunesku, T, Radosavljevic (Grujic) D, Labat, I, Drmanac, R and Crkvenjakov R, DNA
sequencing by hybridization: 100 bases read by a non-gel based method. Proc. Nat. Acad. Sci,
USA, (1991), 88, p 0089-10093
21. Radosavljevic (Grujic), D, Todorovic, D and Crkvenjakov R, Deletion analysis of Duchenne Muscular
DystrophyusingcDNA probesandmultiplexPCR. Neurologica Croatica, (1991),40, 157-164
22. Radosavljevic (Grujic), D, Todorovic, D and Crkvenjakov, R: Analysis of chromosomal deletions in
DMD patients using multiplex PCR and cDNA probes. Journal of Neurological Science (1990),
23. Stevanovic, M, Paunesku, T, Radosavljevic (Grujic), D, Drmanac R and Crkvenjakov R: Variant
chromosomal arrangementof adultbetaglobin genesinrat. Gene, 79 (1989), 139-150
24. Radosavljevic (Grujic), D and Crkvenjakov, R: Genome sequence of rat beta-globin major gene.
Nucleic Acids Research, (1989), 17, 4368
Björn R Weström, Prof
1. Personal data
Full name: Björn Ragnar WESTRÖM
Place and date of birth: Lycksele, Sweden, 8 May 1950
Home address: Doktorsgatan 9C, SE-262 52 Ängelholm, Sweden
Phone; +46 (0)431 18622
Current work address: Department of Cell and Organism Biology, Animal Physiology,
Lund University, Helgonavägen 3B, S-223 62 Lund, Sweden
Phone; +46 (0)46 2229733, Fax; +46 (0)46 222453
2. Academic exams and qualifications
2001 Professor in Zoophysiology, Lund University
1987 Associate Professor in Zoophysiology (Docentkompetens), Lund University
1985 Doctor of Philosophy (Ph.D) in Zoophysiology, Lund University.
Thesis title; Proteinase inhibitors in mammalian blood serum and mammary secretions
with special reference to their function in the growing pig, 1981. (Supervisor Börje
1974 Advanced course in Zoophysiology (D2-level, corresp. to exam work), Lund University
1974 Bachelor of Science (B.Sc) in Chemistry and Biology, Lund University (3 years)
0106-ongoing Professor in Zoophysiology, Dept Cell and Organism Biology, Lund University
(with 50 % research/50 % teaching)
8910-0105 Senior lecturer in Zoophysiology, Dept Animal Physiology, Lund University
8807-8910 Senior researcher, Dept Animal Physiology, Lund University
8207-8806 Postdoctoral fellow, Dept Animal Physiology, Lund University, financed by the
Swedish Natural Science Research Council (NFR)
8107-8206 Assistant, 50%, Dept Animal Physiology, Lund University
8007-8206 Postdoctoral fellow, 50%, Dept Animal Physiology, Lund University
7907-8106 Assistant, 50%, Dept Biology, Lund University
4. Membership in scientific societies
2008 Royal Physiografic Society in Lund
2001-03 The Swedish Research Council for Environment, Agricultural Sciences and Spatial
Planning (FORMAS), Functional development of the digestive system and its impact
on growth of young farm animals. B. Weström, Rådberg, Evilevitch, (516 kSEK/year).
2002–05 The Swedish Agency for Innovation Systems (Vinnova). Lectins and glutamine
derivates improve health around weaning. B. Weström (Total 500 kSEK)
2007–08 Antidiabetic Food Centre/Vinnova. Blood pressure reducing effects of different
fermented plant materials using an animal model. B. Weström (Total 419 kSEK)
6. Academic duties
PhD :Esbjörn Telemo (1986); Bertil Ohlsson (1987); Cynthia de Wit (1987); Gunilla Ekström
(1990); Stefan Pierzynowski (1991); Hans Folkesson (1992); Per Michanek (1994); Niclas Pantzar
(1995); Quan Wang (1995); Mary-Jane Thaela (1997); Pål Lundin (1997); Dan Rantzer (1997);
Pernilla Nejdfors (2000); Klas Rådberg (2001); Lotta Georgsson (2002); Lena Evilevitch (2004);
Ann Linderoth (2006); Shahram Lavasani (2006); Frida Fåk (2008); Annica Thomsson ; Olena
Prykhodko (2008); Sofia Rengman (2009); Olexandr Fedkiv (2009).
Teaching at basic and advanced courses for natural science students:
Lectures in basic Immunology (MOBA01, KLGN01)(1987-ongoing).
Lectures and examination in basic Zoophysiology (BIOC01, BIMM) (1992-ongoing).
Course leadership, lectures, practicals and examination and in advanced Immunology
(BIOR16), 15 credits (1987-ongoing, each semester).
Initiative to and planning, course leadership, lectures and examination in Nutrition Physiology
(BIOR50), 15 credits (2005-ongoing ).
Supervision of 22 research projects (4 credits) within the advanced course in Zoophysiology
Supervision and examination of about 100 projects for master candidates in Immunology and
Zoophysiology 15-30 credits (1976-ongoing).
Adrian Paul HARRISON, Ass Prof
Thorvaldsensvej 19, 2.th, 1871 Frederiksberg C.
Details: Born November 26th 1965, North Ferriby, Yorkshire, England.
British by birth. Danish married since May 1995.
E-mail: firstname.lastname@example.org Phone: 00 45 35 33 25 68 Fax: 00 45 35 33 25 25
1985-88 HND - Higher National Diploma: Credit (Agric.), Harper Adams College, Shrops-
1988-91 BSc - Bachelor of Science: Hons. (2:1) (Agric. Biochem. & Nutr.), University of
Newcastle Upon Tyne, England.
1991-94 D.Phil. - Doctor of Philosophy, University of Cambridge, England. Regulation of
porcine skeletal muscle growth and differentiation, submitted Sept 1994,
examined Feb 1995 and admitted to the Degree Nov 1995.
1991-94 Awarded a BBSRC Research Studentship, Department of Cellular Physiology, The
Babraham Institute, Babraham, Cambridge, CB2 4AT, England.
1994-99 Research Scientist (Forskningsadjunkt), Department of Physiology,
Faculty of Medicine, University of Aarhus, DK-8000 Århus C,
1999-2001 Research Scientist (Forskningsadjunkt), Department of Anatomy &
Physiology, The Royal Veterinary & Agricultural University (KVL),
Grønnegaardsvej 7, DK-1870 Frederiksberg C, Denmark.
2001- Associate Professor, Dept. of Animal and Veterinary Basic
Sciences, Copenhagen University, Faculty of Life Sciences (LIFE
CU), Grønnegaardsvej 7, DK-1870 Frederiksberg C, Denmark.
2007 Professor: Judged, by an International Committee, as being qualified at
the Professor level - Copenhagen University, Faculty of Life Sciences.
Scientific The Nutrition Society, August 1994 Southampton meeting, student
Merits prize for the best oral presentation out of 135 entries.
Fellowships: Awarded an Alfred Benzon Investigator Fellowship (1997 and 1998).
Associate Editor: Journal of Pre-Clinical & Clinical Research.
The Open Bone Journal
Languages: Fluent in Danish – verbal and written. Can understand
Norwegian and Swedish – spoken and written language.
Panels: Advisory Panel: EU COST Action 925: The importance of prenatal
events for postnatal muscle growth in relation to the quality of muscle
Scientific Panel Member: Research School for Animal Production and
Health - RAPH
Funding: 2002 – 1.200.000 kr RAPH – Nutrition and reproduction in harmony – Project
2003 – 1.547.000 kr BRFP II – Understanding the language of muscle
2008 – 1.547.000 kr RAPH – Alpha-ketoglutarate and collagen for
healthy livestock production - Project Leader
2009 – 100.000 $ - Rhodimet Funded Project – Methionine and muscle
function – Co-Project Leader
1) 260013 Production Anatomy & Physiology (50 to 70 students), LIFE, CU
1) 300047 Veterinary Basic Physiology, LIFE, CU
2) 260008 Experimental Animal Nutrition & Physiology, LIFE, CU
3) Basic Animal Production & Nutrition, LIFE, CU
4) Thematic Course: Animal Science, LIFE, CU
5) B3 F09-UE Meat production, LIFE, CU
6) Bio 651 Nutrition Physiology: Guest Lecturer in the Dept. of Zoophysiology at
Lund University, Sweden.
7) MSc/Postgraduate Diploma in Applied Toxicology: Guest Lecturer for the
Safety Pharmacology Module – University of Surrey, UK
Referee for: Acta Physiol Scand; American Journal of Physiology; Muscle &
Nerve; Journal of Applied Physiol.; Zoomorphology; Acta Veterinaria
Scandinavica; Journal of Pharmacology & Toxicology; J.Comparative
Biochemistry & Physiology; Livestock Science; J. of Clinical
Nutrition; International Journal for Vitamin & Nutrition Research;
British Medical Journal; Environmental Science & Pollution Research.
Safety Pharmacology Society Meeting (3rd), Noordwijk aan Zee, The Netherlands.
“Gastrointestinal tract: Models and techniques for use in safety pharmacology” 2003.
Safety Pharmacology Society Meeting (7th),Edinburgh, Scotland. “Gastrointestinal studies” 2007.
British Museum – Gallery Talk – Feb 2009 – ”Olympic Victor´s Dark Ointment” for the
Researchlinks: Dr. Inge Eidemak, Nephrology Dept. RigsHospitalet, Denmark (Renal
failure & muscle weakness project); Prof. Stefan Pierzynowski, Cell Biology Dept. Lund
University, Sweden (Intestinal physiology); Dr. Margrethe Therkildsen, Meat Science Section,
DJF, Tjele, Denmark (Meat quality); Dr. Lennart Friis-Hansen, MD, Dr Med Sci. Dept. of
Clinical Biochemistry kb3011, RigsHospitalet, Denmark.
Wojciech Rzeski, Prof
Place and date of birth (d/m/y): Szubin, Poland; 12-04-1963
Address: Biskupińska 56, 20-830 Lublin, Poland
1. Working experience
1.1 Actual and previous positions
2010 – continuum, Professor, Department of Virology and Immunology, Institute of
Microbiology and Biotechnology, Maria Curie-Skłodowska University, Lublin,
2010 – continuum, Docent, Department of Medical Biology, Institute of
Agricultural Medicine, Lublin, Poland
2006-2009, Docent, Department of Toxicology, Institute of Agricultural Medicine,
2005-2006, Adiunkt, Department of Toxicology, Institute of Agricultural Medicine,
1997-1999, Researcher, Department of Pediatric Neurology, Humboldt University,
2. Education and training
2. 1 Degrees and evaluation of qualification
Associated Professor, Biological Sciences, Faculty of Biology and Earth Sciences,
Maria Curie-Skłodowska University, Lublin, Poland, 2005
Ph.D, Biological Sciences, Faculty of Biology and Earth Sciences, Maria Curie-
Skłodowska University, Lublin, Poland, 1995
MSc, Microbiology, Faculty of Biology and Earth Sciences, Maria Curie-
Skłodowska University, Lublin, Poland, 1987
2.2 Other education
Pedagogic - methods, Maria Curie-Skłodowska University, Lublin, Poland
European Workshop and Postgraduate Training Course UNESCO-ROSTE in
Modern Biotechnology, Czechoslovak Academy of Sciences, Prague,
Biobiz™ Training Workshop, Commercialization of Life Sciences Research
3. Scientific qualifications
3.1 Scientific production / List of the publication (in total 178 publications)
3.1.1 Articles published in scientific journals – peer- review papers (2001 – 2010)
1. Rzeski W., Turski L., Ikonomidou C. (2001): Glutamate antagonists limit tumor growth.
Proc. Natl. Acad. Sci. USA 98, (11), 6372-77.
2. Rzeski W., Paduch R., Klatka J., Kandefer-Szerszeń M., Stepulak A., Pożarowski P,
Zdzisińska B. (2002): Establishment and preliminary characterization of the two cell lines
derived from larynx carcinoma. Folia Histochem. Cytobiol., 40, 195-196.
3. Rzeski W., Ikonomidou C., Turski L. (2002): Glutamate antagonists limit tumor growth.
Biochem. Pharmacol. 64, 8, 1195-1200.
4. Tchórzewski M., Krokowski D., Rzeski W., Issinger O-G., Grankowski N. (2003): The
subcellular distribution of the human ribosomal „stalk” components: P1, P2 and P0
proteins. Int. J. Bioch.Cell Biol., 35, 203-211.
5. Hansen H.H., Briem T., Dzietko M., Sifringer M., Voss A., Rzeski W., Zdzisinska B.,
Thor F., Heumann R., Stepulak A., Bittigau P., Ikoonomidou C. (2004): Mechanisms
leading to disseminated apoptosis following NMDA receptor blockade in the developing
brain. Neurobiol. Dis., 16, 440-453.
6. Rzeski W., Pruskil S., Macke A., Felderhoff-Mueser U., Reiher A.K., Hoerster F., Jansma
C., Jarosz B., Stefovska V., Bittigau P., Ikonomidou C. (2004): Anticancer agents are
potent neurotoxins in vitro and in vivo. Ann. Neurol., 56, (3), 351-360.
7. Rzeski W., Turski L., Ikonomidou C. (2005): Anticancer effects of glutamate antagonists.
W: Gill S. and Pulido O. (red). Glutamate receptors in peripheral tissue: Excitatory
transmission outside the CNS. Kluwer Academic/Plenum Publishers, New York, USA, 4,
8. Ginalska G., Osinska M., Uryniak A., Urbanik-Sypniewska T., Belcarz A., Rzeski W.,
Wolski A. (2005): Antimicrobial activity of gentamycin-bonded gelatin-sealed
polyterephthalate ethylene vascular prostheses. Eur. J. Vasc. Endovasc. Surg., 29, 419-
9. Rzeski W., Kocki T., Dybel A., Wejksza K., Zdzisińska B., Kandefer-Szerszeń M., Turski
W.A., Okuno E., Albrecht J. (2005): Demonstration of kynurenine aminotransferases I and
II and characterization of kynurenic acid synthesis in cultured cerebral cortical neurons. J.
Neurosci. Res., 80, 677-682.
10. Wejksza K., Rzeski W., Okuno E., Kandefer-Szerszen M., Albrecht J., Turski W.A.
(2005): Demonstration of kynurenine aminotransferases I and II and characterization of
kynurenic acid synthesis in OLN-93 oligodendrocyte cell line. Neurochem. Res., 30, (8),
11. Stepulak A., Sifringer M., Rzeski W., Endesfelder S., Gratopp A., Pohl E., Bittigau P.,
Felderhoff-Mueser U., Kaindl A.M., Bücher C., Hansen H.H., Stryjecka-Zimmer M.,
Turski L., Ikonomidou C. (2005): NMDA antagonist inhibits the extracellular signal-
regulated kinase pathway and suppresses cancer growth. Proc. Natl. Acad. Sci. USA, 102,
12. Parada-Turska J., Rzeski W., Zgrajka W., Majdan M., Kandefer-Szerszeń M., Turski W.A.
(2006): Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid
inhibits proliferation of synoviocytes in vitro. Rheumatol. Int., 26 (5), 422-426.
13. Wejksza K., Rzeski W., Turski W.A., Hilgier W., Dybel A., Albrecht J. (2006): Amonia at
pathophysiologically relevant concentrations activates kynurenic acid synthesis in cultured
astrocytes and neurons. Neurotoxicology, 27, (4), 615-618.
14. Parada-Turska J., Rzeski W., Majdan M., Kandefer-Szerszeń M.,Turski W. (2006): Effect
of glutamate antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro.
Eur. J. Pharmacol., 535, (1-3), 95-97.
15. Kuc D., Rahnama M., Tomaszewski T., Rzeski W., Wejksza K., Urbanik-Sypniewska T.,
Parada-Turska J., Wielosz M., Turski W.A. (2006): Does kynurenic acid naturally
occurring in human saliva influence oral microflora? Parmacol. Rep., 58, (3), 393-398.
16. Rzeski W., Stepulak A., Szymański M., Sifringer M., Kaczor J., Wejksza K., Zdzisińska
B., Kandefer-Szerszeń M. (2006): Betulinic acid decreases expression of bcl-2 and cyclin
D1, inhibits proliferation, migration and induces apoptosis in cancer cells. Naunyn
Schmiedeberg’s Arch. Pharmacol., 374, 11-20.
17. Rzeski W., Matysiak J., Kandefer-Szerszeń M. (2007): Anticancer, neuroprotective
activities and computational studies of 2-amino-1,3,4-thiadiazole based compound. Bioorg.
Med. Chem., 15, (9), 3201-3207.
18. Parada-Turska J., Paduch R., Majdan M., Kandefer-Szerszeń M., Rzeski W. (2007):
Antiproliferative activity of parthenolide against three human cancer cell lines and human
umbilical vein endothelial cells. Pharmacol. Rep., 59, (2), 233-237. MNiSW –
19. Stepulak A., Sifringer M., Rzeski W., Brocke K., Gratopp A., Pohl E.E., Turski L.,
Ikonomidou C. (2007): AMPA antagonists inhibit the extracellular signal regulated kinase
pathway and suppress lung cancer growth. Cancer Biol. Ther., 6 (12), 1908-1915.
20. Jakubowicz-Gil J., Rzeski W., Zdzisińska B., Dobrowolski P., Gawron A. (2008): Cell
death and neuronal arborization upon quercetin treatment in rat neurons. Acta Neurobiol.
Exp. (Wars), 68, (2), 139-146.
21. Parada-Turska J., Mitura A., Brzana W., Jabłoński M., Majdan M., Rzeski W. (2008):
Parthenolide inhibits proliferation of fibroblast-like synoviocytes in vitro. Inflammation,
31 (4), 281-285.
22. Juszczak M., Matysiak J., Brzana W., Niewiadomy A., Rzeski W. (2008): Evaluation of
antiproliferative activity of 2-(monohalogenphenylamino)-5-(2,4-dihydroxyphenyl)-1,3,4
thiadiazoles. ArzneimForsch/DrugRes., 58, (7), 353-357.
23. Stepulak A., Rzeski W., Sifringer M., Gratopp A., Kupisz K., Turski L., Ikonomidou C.
(2008): Fluoxetine inhibits the extracellular signal regulated kinase pathway and
suppresses growth of cancer cells. Cancer Biol. Ther., 7 (10), 1685 – 1693.
24. Jakubowicz-Gil J., Rzeski W., Zdzisinska B., Piersiak T., Weiksza K., Glowniak K.,
Gawron A (2008) Different sensitivity of neurons and
neuroblastoma cells to quercetin treatment. Acta Neurobiol. Exp. (Wars) 68 (4), 463-476.
25. Belcarz A., Ginalska G., Zalewska J., Rzeski W., Slosarczyk A., Kowalczuk D.,
Godlewski P., Niedzwiadek J. (2008): Covalent coating of hydroxyapatite by keratin
stabilizes gentamicin release. J. Biomed. Mater. Res. Part B: Appl. Biomater. 89B, (1),
26. Paduch R., Rzeski W., Klatka J. (2009): The effect of cisplatin on human larynx
carcinoma cell motility. Folia Histochem. Cytobiol., 47, (1), 75-79.
27. Wejksza K., Rzeski W., Turski W.A. (2009): Protective effects of kynurenic acid against
homocysteine induced impairment of endothelial cell function. In vitro study. Pharmacol.
Rep., 61 (4), 541-546.
28. Stepulak A., Luksch H., Gebhardt C., Uckerman O., Sifringer M., Rzeski W., Turski L.,
Ikonomidou C. (2009): Expression of glutamate receptors in cancer cell lines. Histochem.
Cell Biol., 132 (4), 435-45.
29. Rzeski W., Stepulak A., Szymański M., Juszczak M., Grabarska A., Sifringer M., Kaczor
J., Kandefer-Szerszeń M. (2009): Betulin elicits anticancer effects in tumor primary
cultures and cell lines In vitro. Basic Clin. Pharmacol. Toxicol., 105 (6), 425-432.
30. Lemieszek M.K., Langner E., Kaczor J., Kandefer-Szerszeń M., Sanecka B.,
Mazurkiewicz W., Rzeski W. (2009): Anticancer effect of fraction isolated from medicinal
birch polypore mushroom, Piptoporus betulinus (Bull.: Fr.) P. Karst.
(Aphyllophoromycetideae): in vitro studies. Int. J. Med. Mushrooms, 11 (4), 351-364.
31. Jakubowicz-Gil J., Langner E., Wertel I., Rzeski W. (2010): Temodal, quercetin and cell
death in the MOGGCCM astrocytoma cell line. Chem. Biol. Interact., 188 (1):190-203.
3.2 Scientific leadership
Evaluation of anticancer activity of New aminothiadiazole derivatives ,grant no N
N401 223734, Ministry of Science and Higher Education, 2008-2011
Anticancer activity of alfa-ketoglutarate, Essentys, Sweden
Anticancer activity of heated potato fibre Potex, Essentys, Sweden
Kynurenic acid in brain and periphery – its role in physiology and pathology,
Foundation for Polish Science, Mistrz Programme (Prof. Waldemar Turski), 2008-2011
Olena Prykhod'ko, PhD
Date of birth 1979-06-29
Marital Status Married
Children Two sons (born 2006 and 2008)
Languages Ukrainian, Russian, English, Swedish
Hobby Photographing, glass bead weaving
Contact: +46 46 730488609
SE-226 46 Lund
2005-2008, PhD (Zoological Cell Biology)
Department of Cell and Organism Biology, Lund University, Sweden
2000-2001, MSc (Biochemistry) (with honours)
Department of Biochemistry and Biophysics, Dnepropetrovsk National University, Ukraine
1996-2000, BSc (Biology) (with honours)
Dnepropetrovsk National University, Dnepropetrovsk, Ukraine
May 2009 - present
Research projects 2009-2010:
- Role of the immune system in gut development of young mammals.
- Role of pancreatic enzymes in gut development and small intestinal mucosal
PhD studies with 15% of teaching duties (Dept of Cell and Organism Biology, Lund
University, Sweden) Theses: “Involvement of the immune system in
phytohaemagglutinin-induced structural and functional precocious maturation of the
gut in young rats.”
Supervisors: Prof. B. Weström, Prof. S. Pierzynowski
Faculty opponent: Prof. E. Telemo, Dept of Rheumatology and Inflammation
Research, University of Gothenburg, Sweden
Research project in animal physiology (Dept of Cell and Organism Biology Lund
- Effect of exposure to the lectin, phythohaemagglutinin (PHA), on gut of young
Supervisors: Prof. B. Weström, Prof. S. Pierzynowski
Postgraduate practice in inflammatory research (Dept of Medical Microbiology,
Dermatology & Infection (MMDI), Lund University, Sweden)
- Inflammation and regulation of adhesion molecules expressing in gastric and biliary
epithelial cell-lines after bacterial infection with Helicobacter spp. Implication of
Supervisors: Prof. T. Wädstrom, Ass Prof. Å. Ljungh
Graduate research (diploma work) (Dept of Biochemistry and Biophysics,
Dnepropetrovsk National University, Ukraine)
- The influence of acute and chronic ionizing irradiation on the epithelial proliferation
and calcitonin expression in C-cells of thyroid gland in rats. Implication of histological
and immune methods.
Supervisors: Prof. G. Ushakova, PhD. I. Kornilovska.
- Lab assistant (Nutritional physiology BIOR50, Immunology BIOR16) at Lund
- Supervision of Project- and Master-students (Olof Torper Ht 2006, Jennifer Pieper
Vt 2007, Lidia Kopacz Vt 2007, Bo Lindberg Ht 2007, Krister Andersson Vt2009,
Hamid Bashar Vt2010)
May 2009 - present
Researcher at Lund University, Dept of Biology (Sölvegatan 35 C, SE 223 62 Lund,
Tel: +46 46 2229732, E-mail: Olena.Prykhodko@cob.lu.se)
Oct 2009 – June 2010
Scientist in vivo, project assistant, Probi AB (Ideon Gamma 1, Sölvegatan 41, SE -
223 70 Lund, Sweden)
Laboratory assistant, research worker, at Morphological laboratory "BIONTEC"
collaborating with Center of Molecular Physiology, National Academy of Science,
Clinical research, establishing of diagnostic techniques:
Reviewer in peer-reviewed journals: Livestock Science (2), Pharmacological Research (1).
Participant in congresses and conferences.
GRANTS AND AWARDS:
Participant in Visby program 2004 supported by Swedish Institute.
Personal grants supported by Kgl. Fysiografiska Sällskapet i Lund and Dir A. Påhlssons Stift
by more than 200 000 SEK for running projects.
Bibliography been invited for publishing in Marquis Who's Who in the World.
PATENTS AND PUBLICATIONS
1 patent, 7 articles in peer-reviewed journals.
RELEVANT TECHNICHAL SKILLS
- Scientist in vivo (rodents, ungulates), i.e., stomach-tube feeding, s.c., i.p., i.v. injections,
behaviour test, blood pressure (CODA 2 system) ect.
- Anaesthesia, euthanasia, obduction, blood/tissue/organs sampling, fixation
- Histological technique (cryo and paraffin sections)
- Immune cell isolation (blood, lymphoid tissue)
- Histological staining methods: Hematoxylin-Eosin, May-Grunwald – Giemsa.
- Immunohistochemistry and immunofluorescent analysis
- Tissue morphometry (ImageJ, ImagePro software)
- Enzyme-linked immunosorbent assay (ELISA)
- Agarose electrophoresis, immunoassays